- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05289765
Efficacy of Gel With Ecological Extra Virgin Olive Oil in Peristomal Skin Hygiene (gAOVEstoma)
Efficacy of Gel With Ecological Extra Virgin Olive Oil in Peristomal Skin Hygiene. Non-inferiority Randomised Controlled Clinical Trial. A Pilot Study.
Study Overview
Status
Detailed Description
This is a non-inferiority randomised controlled clinical trial conducted with parallel groups as a pilot study. The main aim of this research is to evaluate the efficacy of the application of an Ecological Extra Virgin Olive Oil (eEVOO) neutral gel in peristomal skin hygiene in individuals with colostomy and ileostomy compared to the application of a neutral gel without eEVOO or any other olive oil-derived products. The specific objective is to determine the safety of the application of this gel in terms of the absence of adverse effects upon placement and removal of the device/bag and peristomal skin complications.
The setting are the Stoma care unit at the Virgen de las Nieves University Hospital and the San Cecilio University Hospital (Granada, Spain).
The response variable will be measured using the DET scale, which assesses tissue colouration, integrity, and overgrowth in peristomal skin. Skin moisture and fat will also be measured, as well as the individuals' perceptions of their stoma.The safety of the intervention will be determined by the absence of adverse effects at different levels: Difficulty in placing and removing the device/bag; Local reactions such as itching, pain, or stinging. A visual analogue scale will be used; Any other chemical, infectious, mechanical, or immunological complications of interest.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Granada, Spain, 18014
- Hospital Universitario Virgen de las Nieves
-
Granada, Spain, 18016
- Hospital Universitario San Cecilio
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Individuals with a colostomy or ileostomy.
- Individuals using one- or two-piece devices.
- Individuals demonstrating knowledge and skills in stoma self-care. The criterion is to score between 4 and 5 on the following stoma hygiene-related indicators of the Nursing Outcomes Classification (NOC): "Knowledge: ostomy care [1829]" and "Self-care of the ostomy [1615]".
- Individuals agreeing to participate in the study
Exclusion Criteria:
- Individuals with involvement of the peristomal skin area as measured by the DET scale with a score of at least 1 in one of the three evaluation domains (less than 25% involvement).
- Individuals undergoing treatment for the condition that led to their ostomy as this may affect the condition of the skin.
- Terminally ill persons.
- Individuals with a known allergy to any of the gel components, both in the experimental group and in the active control group.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1
Ecological Extra Virgin Olive Oil
|
A natural neutral Ecological Extra Virgin Olive Oil based gel will be applied to the peristomal skin area at the time of peristomal skin care.
Hygiene shall be performed by patients themselves following a standardised procedure recommended by Clinical Guideline.
|
Active Comparator: Group 2
Conventional
|
A conventional neutral gel, without Ecological Extra Virgin Olive Oil or any other olive oil-derived products will be applied to the peristomal skin area at the time of peristomal skin care.
Hygiene shall be performed by patients themselves following a standardised procedure recommended by Clinical Guideline
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from DET (Discolouration, Erosion, Tissue overgrowth) in Peristomal Skin.
Time Frame: Change from baseline at 4 weeks and 8 weeks.
|
Discolouration, Erosion, Tissue overgrowth will be measured using the DET scale. DET scale examinates the peristomal skin based on the descriptions in affected area and severity of the three domains. Maximum points in each domain: 3 points for the size of the affected area and 2 points for the severity. First of all, the examiner assesses the size of the area affected in each of the three domains and score based on: 0 (Unaffected); 1 (<25%); 2 (25-50%); 3 (>50%). Then, the examiner assesses the severity in each of the three domains. Notes: If there is no discolouration then the skin is healthy - the area score is 0 and the total DET score must be 0. In a situation where a large area of skin with low severity includes a small area with a high severity, the highest severity should always be scored even though the area is small. Total score (maximum 15) is calculated by adding all of the subscores from each domain together. Higher scores mean a worse outcome. |
Change from baseline at 4 weeks and 8 weeks.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fat in Peristomal Skin.
Time Frame: Change from baseline at 4 weeks and 8 weeks.
|
Level of fat in skin will be collected by means of a digital skin detector.
|
Change from baseline at 4 weeks and 8 weeks.
|
Skin moisture in Peristomal Skin.
Time Frame: Change from baseline at 4 weeks and 8 weeks.
|
Level of skin moisture will be collected by means of a digital skin detector.
|
Change from baseline at 4 weeks and 8 weeks.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Perception about stoma self-care.
Time Frame: Change from baseline at 4 weeks and 8 weeks.
|
Two indicators of the outcome "Self-care of the ostomy [1615]" from Nursing Outcome Classification (NOC) will be used: "Appears comfortable viewing stoma [161503]" and "Expresses acceptance of ostomy [161519]".
Both indicators are measured using a Likert scale from 1 to 5. Higher scores mean a better outcome.
|
Change from baseline at 4 weeks and 8 weeks.
|
Questionnaire to evaluate difficulty in placing and removing the device/bag
Time Frame: Change from baseline at 4 weeks and 8 weeks.
|
The questionnaire include two items with dichotomous answer (Yes/No).
These items asseses the difficulty in placing and removing the device/bag on the peristomal skin in relation to the correct use of the adhesive included in these devices.
Additionally, other problems reported by the patients in placing and removing the device/bag will be collected.
|
Change from baseline at 4 weeks and 8 weeks.
|
Local reactions in stoma or peristomal skin
Time Frame: Change from baseline at 4 weeks and 8 weeks.
|
Local reactions such as itching, pain, or stinging.
A visual analogue scale from 0 to 10 (score) will be used.
Higher scores mean a worse outcome.
|
Change from baseline at 4 weeks and 8 weeks.
|
Peristomal skin alterations
Time Frame: Change from baseline at 4 weeks and 8 weeks.
|
Any other chemical, infectious, mechanical, or immunological complications of interest
|
Change from baseline at 4 weeks and 8 weeks.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: César Hueso Montoro, PhD, Department of Nursing, University of Granada, Granada, Spain
- Principal Investigator: Concepción Capilla Díaz, PhD, Department of Nursing, University of Granada, Granada, Spain
- Principal Investigator: Francisco Pedro García Fernández, PhD, Department of Nursing, University of Jaén, Jaén, Spain
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ileostomy - Stoma
-
Chang Gung Memorial HospitalConvaTect, TaiwanUnknownStoma Ileostomy | Stoma ColostomyTaiwan
-
Coloplast A/SCompleted
-
11 Heath and Technologies LimitedThe Cleveland ClinicUnknownIleostomy; Complications | Ileostomy - StomaUnited States
-
Massachusetts General HospitalRecruitingSurgery | Ileostomy - Stoma | Colostomy StomaUnited States
-
BBraun Medical SASRecruitingEnterostomy | Stoma Ileostomy | Stoma ColostomySpain
-
Hospital de BasurtoAlberto Loizate Totoricaguena; Pedro García AlonsoUnknownIleostomy; Complications | Ileostomy - Stoma | Stoma Ileostomy | Ileus ParalyticSpain
-
Coloplast A/SCompleted
-
DHQ mardanDHQ HOSPITAL MARDANCompleted
-
Coloplast A/SIWK Health Centre; Children's National; Driscoll Children's HospitalWithdrawn
-
University of Kansas Medical CenterCompletedStoma IleostomyUnited States